The effective molecular characteristics of PD-1 inhibitor combination regimen as the first-line treatment for Chinese patients with HER2-positive gastric cancer: a real-world retrospective analysis study
The results suggested that patients with HER2-positive GC could benefit from PD-1 inhibitors combination with trastuzumab and chemotherapy, especially patients with HER-2 FISH more than six and <i>TP53</i> mutations.
Authors
- Yiyi Yu (ORCID: https://orcid.org/0000-0002-8444-0235)
- Yuehong Cui (ORCID: https://orcid.org/0000-0002-2551-7239)
- Bin Guan (ORCID: https://orcid.org/0000-0001-5986-5189)
- Yan Wang (ORCID: https://orcid.org/0000-0002-8302-3704)
- Qian Li (ORCID: https://orcid.org/0000-0002-1653-6243)
- Debin Sun
- Shan Yu (ORCID: https://orcid.org/0000-0002-5610-6408)
- Lingyun Zhang
- Wei Li (ORCID: https://orcid.org/0009-0001-8671-6362)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Genecast (China) (CN)
- YangPu Geriatric Hospital (CN)
Publication Details
- Journal
- Translational Gastroenterology and Hepatology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.21037/tgh-24-95
- Citations
- 1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.52